Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract
- PMID: 25659885
- DOI: 10.1016/j.ijrobp.2014.11.028
Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract
Abstract
Purpose: To identify dosimetric predictors of hepatobiliary (HB) toxicity associated with stereotactic body radiation therapy (SBRT) for liver tumors.
Methods and materials: We retrospectively reviewed 96 patients treated with SBRT for primary (53%) or metastatic (47%) liver tumors between March 2006 and November 2013. The central HB tract (cHBT) was defined by a 15-mm expansion of the portal vein from the splenic confluence to the first bifurcation of left and right portal veins. Patients were censored for toxicity upon local progression or additional liver-directed therapy. HB toxicities were graded according to Common Terminology Criteria for Adverse Events version 4.0. To compare different SBRT fractionations, doses were converted to biologically effective doses (BED) by using the standard linear quadratic model α/β = 10 (BED10).
Results: Median follow-up was 12.7 months after SBRT. Median BED10 was 85.5 Gy (range: 37.5-151.2). The median number of fractions was 5 (range: 1-5), with 51 patients (53.1%) receiving 5 fractions and 29 patients (30.2%) receiving 3 fractions. In total, there were 23 (24.0%) grade 2+ and 18 (18.8%) grade 3+ HB toxicities. Nondosimetric factors predictive of grade 3+ HB toxicity included cholangiocarcinoma (CCA) histology (P<.0001), primary liver tumor (P=.0087), and biliary stent (P<.0001). Dosimetric parameters most predictive of grade 3+ HB toxicity were volume receiving above BED10 of 72 Gy (VBED1072) ≥ 21 cm(3) (relative risk [RR]: 11.6, P<.0001), VBED1066 ≥ 24 cm(3) (RR: 10.5, P<.0001), and mean BED10 (DmeanBED10) cHBT ≥14 Gy (RR: 9.2, P<.0001), with VBED1072 and VBED1066 corresponding to V40 and V37.7 for 5 fractions and V33.8 and V32.0 for 3 fractions, respectively. VBED1072 ≥ 21 cm(3), VBED1066 ≥ 24 cm(3), and DmeanBED10 cHBT ≥14 Gy were consistently predictive of grade 3+ toxicity on multivariate analysis.
Conclusions: VBED1072, VBED1066, and DmeanBED10 to cHBT are associated with HB toxicity. We suggest VBED1072 < 21 cm(3) (5-fraction: V40 < 21 cm(3); 3-fraction: V33.8 < 21 cm(3)), VBED1066 < 24 cm(3) (5-fraction: V37.7 < 24 cm(3); 3-fraction: V32 < 24 cm(3)) as potential dose constraints for the cHBT when clinically indicated.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):486-93. doi: 10.1016/j.ijrobp.2009.08.020. Epub 2010 Mar 28. Int J Radiat Oncol Biol Phys. 2010. PMID: 20350791 Clinical Trial.
-
Central liver toxicity after SBRT: An expanded analysis and predictive nomogram.Radiother Oncol. 2017 Jan;122(1):130-136. doi: 10.1016/j.radonc.2016.10.024. Epub 2016 Nov 16. Radiother Oncol. 2017. PMID: 27865544
-
Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system.Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1006-11. doi: 10.1016/j.ijrobp.2012.09.012. Epub 2012 Oct 23. Int J Radiat Oncol Biol Phys. 2013. PMID: 23102838
-
An emerging role for radiation therapy in the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma.Surg Oncol Clin N Am. 2014 Apr;23(2):353-68. doi: 10.1016/j.soc.2013.10.007. Epub 2013 Dec 7. Surg Oncol Clin N Am. 2014. PMID: 24560114 Review.
-
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.Cancer Control. 2017 Jul-Sep;24(3):1073274817729259. doi: 10.1177/1073274817729259. Cancer Control. 2017. PMID: 28975831 Free PMC article. Review.
Cited by
-
Pencil Beam Scanning Carbon Ion Radiotherapy for Hepatocellular Carcinoma.J Hepatocell Carcinoma. 2023 Dec 29;10:2397-2409. doi: 10.2147/JHC.S429186. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 38169909 Free PMC article.
-
Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma.Front Oncol. 2023 Jul 24;13:1193762. doi: 10.3389/fonc.2023.1193762. eCollection 2023. Front Oncol. 2023. PMID: 37554167 Free PMC article. Review.
-
Inter- and intrafraction dose variations in robotic stereotactic body radiation therapy (SBRT) for perihilar cholangiocarcinoma in the prospective phase I STRONG trial.Front Oncol. 2023 Mar 8;13:1114737. doi: 10.3389/fonc.2023.1114737. eCollection 2023. Front Oncol. 2023. PMID: 36969072 Free PMC article.
-
Characterization of rib fracture development following liver directed stereotactic body radiation therapy.J Radiosurg SBRT. 2022;8(2):109-116. J Radiosurg SBRT. 2022. PMID: 36275138 Free PMC article.
-
Stereotactic radiotherapy for intrahepatic cholangiocarcinoma.World J Gastrointest Oncol. 2022 Aug 15;14(8):1478-1489. doi: 10.4251/wjgo.v14.i8.1478. World J Gastrointest Oncol. 2022. PMID: 36160742 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical